This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, M. W. Articles by King, S. B. Search for Related Content PubMed PubMed Citation Articles by Liu, M. W. Articles by King, S. B., 3d

Circulation, Vol 81, 1089-1093, Copyright © 1990 by American Heart Association

ARTICLES

Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit

MW Liu, GS Roubin, KA Robinson, AJ Black, JA Hearn, RJ Siegel and SB King 3d
Andreas Gruentzig Cardiovascular Center, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30322.

Trapidil (triazolopyrimidine) possesses activity against platelet- derived growth factor-induced cellular proliferation in vitro and intimal proliferation in vivo. The objective of this study was to determine if trapidil could prevent restenosis in experimentally induced atherosclerotic rabbits. New Zealand White rabbits with preexisting iliac arterial lesions induced by balloon deendothelialization underwent balloon angioplasty. Arteriography was performed before, immediately after, and 4 weeks after the balloon dilatation. Tissue sections of the dilated arterial segment were also analyzed morphometrically. Seventeen rabbits were randomized to two groups: a control group (n = 8) and a trapidil-treated group (n = 9). The treatment group received 30 mg/kg s.c. trapidil twice daily. The angiographic luminal diameters before and after dilatation were similar. At the 4-week restudy, there was a significant preservation of luminal diameter in the trapidil group compared with the control group (1.27 +/- 0.20 vs. 0.94 +/- 0.48 mm, respectively; p less than 0.005). When luminal diameters immediately after dilatation were compared with diameters at the 4-week restudy (i.e., when the degree of restenosis was assessed), there was a greater luminal diameter reduction in the control group than in the trapidil group (0.70 +/- 0.44 vs. 0.30 +/- 0.25 mm, respectively; p = 0.005). By morphometric analyses, the luminal areas were also greater in the trapidil group than the control group (0.80 +/- 0.25 vs. 0.57 +/- 0.33 mm2, respectively; p = 0.03). Intimal thickness was significantly less for the trapidil group than for the control group (0.33 +/- 0.15 vs. 0.44 +/- 0.15 mm, respectively; p = 0.01), as well as medial thickness (0.09 +/- 0.03 vs. 0.11 +/- 0.03 mm, respectively; p = 0.01). In this study, trapidil significantly increased the luminal area and reduced the intimal thickness in the atherosclerotic rabbit iliac artery after balloon angioplasty.

This article has been cited by other articles:

				M. Takikita-Suzuki, M. Haneda, M. Sasahara, M. K. Owada, T. Nakagawa, M. Isono, S. Takikita, D. Koya, K. Ogasawara, and R. Kikkawa Activation of Src Kinase in Platelet-Derived Growth Factor-B-Dependent Tubular Regeneration after Acute Ischemic Renal Injury Am. J. Pathol., July 1, 2003; 163(1): 277 - 286. [Abstract] [Full Text] [PDF]

				P.W. Serruys, D.P. Foley, M. Pieper, J.A. Kleijne, and P.J. de Feyter on behalf of the TRAPIST investigators The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound Eur. Heart J., October 2, 2001; 22(20): 1938 - 1947. [Abstract] [PDF]

				P. Cirillo, P. Golino, M. Ragni, C. Battaglia, F. Pacifico, S. Formisano, C. Buono, M. Condorelli, and M. Chiariello Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors Cardiovasc Res, July 1, 1999; 43(1): 210 - 218. [Abstract] [Full Text] [PDF]

				H. M. Nugent, C. Rogers, and E. R. Edelman Endothelial Implants Inhibit Intimal Hyperplasia After Porcine Angioplasty Circ. Res., March 5, 1999; 84(4): 384 - 391. [Abstract] [Full Text] [PDF]

				D. Bönisch, A.-A. Weber, M. Wittpoth, M. Osinski, and K. Schrör Antimitogenic Effects of Trapidil In Coronary Artery Smooth Muscle Cells by Direct Activation of Protein Kinase A Mol. Pharmacol., August 1, 1998; 54(2): 241 - 248. [Abstract] [Full Text]

				A. Lafont and D. Faxon Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res, July 1, 1998; 39(1): 50 - 59. [Full Text] [PDF]

				J.J.F. Belch, J.W. Shaw, G. Kirk, M. McLaren, R. Robb, C. Maple, and P. Morse The White Blood Cell Adhesion Molecule E-Selectin Predicts Restenosis in Patients With Intermittent Claudication Undergoing Percutaneous Transluminal Angioplasty Circulation, April 15, 1997; 95(8): 2027 - 2031. [Abstract] [Full Text]

				C. Rogers and E. R. Edelman Endovascular Stent Design Dictates Experimental Restenosis and Thrombosis Circulation, June 15, 1995; 91(12): 2995 - 3001. [Abstract] [Full Text]

				E. R. Edelman, M. Simons, M. G. Sirois, and R. D. Rosenberg c-myc in Vasculoproliferative Disease Circ. Res., February 1, 1995; 76(2): 176 - 182. [Abstract] [Full Text]